RU2012140052A - Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств - Google Patents
Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств Download PDFInfo
- Publication number
- RU2012140052A RU2012140052A RU2012140052/15A RU2012140052A RU2012140052A RU 2012140052 A RU2012140052 A RU 2012140052A RU 2012140052/15 A RU2012140052/15 A RU 2012140052/15A RU 2012140052 A RU2012140052 A RU 2012140052A RU 2012140052 A RU2012140052 A RU 2012140052A
- Authority
- RU
- Russia
- Prior art keywords
- dsm
- composition
- deposited
- lactobacillus
- use according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 28
- 241000894006 Bacteria Species 0.000 title claims abstract 11
- 239000006041 probiotic Substances 0.000 title claims abstract 7
- 230000000529 probiotic effect Effects 0.000 title claims abstract 7
- 235000018291 probiotics Nutrition 0.000 title claims abstract 7
- 208000026278 immune system disease Diseases 0.000 title 1
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract 18
- 241000186684 Lactobacillus pentosus Species 0.000 claims abstract 12
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract 9
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 9
- 235000020299 breve Nutrition 0.000 claims abstract 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract 6
- 210000000987 immune system Anatomy 0.000 claims abstract 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract 6
- 230000007170 pathology Effects 0.000 claims abstract 6
- 230000000069 prophylactic effect Effects 0.000 claims abstract 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract 6
- 230000001580 bacterial effect Effects 0.000 claims abstract 5
- 206010003645 Atopy Diseases 0.000 claims abstract 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims abstract 3
- 206010016946 Food allergy Diseases 0.000 claims abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 3
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims abstract 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract 3
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 3
- 230000007815 allergy Effects 0.000 claims abstract 3
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 208000010668 atopic eczema Diseases 0.000 claims abstract 3
- 230000001413 cellular effect Effects 0.000 claims abstract 3
- 208000024711 extrinsic asthma Diseases 0.000 claims abstract 3
- 230000007813 immunodeficiency Effects 0.000 claims abstract 3
- 238000004113 cell culture Methods 0.000 claims abstract 2
- 244000005700 microbiome Species 0.000 claims abstract 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 244000199866 Lactobacillus casei Species 0.000 claims 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 2
- 229940017800 lactobacillus casei Drugs 0.000 claims 2
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 210000003850 cellular structure Anatomy 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000013325 dietary fiber Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
1. Композиция, содержащая по меньшей мере одну культуру пробиотических бактерий, выбранную из группы, включающей следующие бактериальные культуры, депонированные в немецкой коллекции микроорганизмов и клеточных культур (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)):Lactobacillus salivarius (LS01) DSM 22775, депонированный 23.07.2009;Bifidobacterium breve (BR03) DSM 16604, депонированный 20.07.2004;Lactobacillus pentosus (LPS01) DSM 21980, депонированный 14.11.2008;Streptococcus thermophilus (FP4) DSM 18616, депонированный 13.09.2006;Lactobacillus casei ssp.rhamnosus (LR04) DSM 16605, депонированный 20.07.2004; иLactobacillus acidophilus (LA02) DSM 21717, депонированный 06.08.2008,для применения в лечении патологий, ассоциированных с изменениями иммунной системы.2. Композиция по п.1 для применения в профилактическом и/или терапевтическом лечении патологий, ассоциированных с изменениями иммунной системы, выбранных из группы, включающей аллергии, атопию, аллергический ринит, пищевую гиперчувствительность, атопический дерматит, экзему, астму или иммунодефициты.3. Композиция по п.1 или 2 для применения в профилактическом и/или терапевтическом лечении атопического дерматита.4. Композиция для применения по п.1, содержащая по меньшей мере одну культуру пробиотических бактерий, выбранную из группы, включающей Lactobacillus salivarius (LS01) DSM 22775, Bifidobacterium breve (BR03) DSM 16604 и Lactobacillus pentosus (LPS 01) DSM 21980.5. Композиция для применения по п.4, состоящая из Lactobacillus salivarius (LS01) DSM 22775, Bifidobacterium breve (BR03) DSM 16604 и L.pentosus (LPS01) DSM 21980.6. Композиция для применения по п.4, состоящая из Lactobacillus salivarius (LS01) DSM 22775 и Bifidobacterium breve (BR03) DSM 16604.7. Композиция для применения по п.1, где указанные бактериальные культуры представлены в указанных композициях в форме живых бактерий, мертвых бактерий или клеточных компонентов, клеточных экст
Claims (15)
1. Композиция, содержащая по меньшей мере одну культуру пробиотических бактерий, выбранную из группы, включающей следующие бактериальные культуры, депонированные в немецкой коллекции микроорганизмов и клеточных культур (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)):
Lactobacillus salivarius (LS01) DSM 22775, депонированный 23.07.2009;
Bifidobacterium breve (BR03) DSM 16604, депонированный 20.07.2004;
Lactobacillus pentosus (LPS01) DSM 21980, депонированный 14.11.2008;
Streptococcus thermophilus (FP4) DSM 18616, депонированный 13.09.2006;
Lactobacillus casei ssp.rhamnosus (LR04) DSM 16605, депонированный 20.07.2004; и
Lactobacillus acidophilus (LA02) DSM 21717, депонированный 06.08.2008,
для применения в лечении патологий, ассоциированных с изменениями иммунной системы.
2. Композиция по п.1 для применения в профилактическом и/или терапевтическом лечении патологий, ассоциированных с изменениями иммунной системы, выбранных из группы, включающей аллергии, атопию, аллергический ринит, пищевую гиперчувствительность, атопический дерматит, экзему, астму или иммунодефициты.
3. Композиция по п.1 или 2 для применения в профилактическом и/или терапевтическом лечении атопического дерматита.
4. Композиция для применения по п.1, содержащая по меньшей мере одну культуру пробиотических бактерий, выбранную из группы, включающей Lactobacillus salivarius (LS01) DSM 22775, Bifidobacterium breve (BR03) DSM 16604 и Lactobacillus pentosus (LPS 01) DSM 21980.
5. Композиция для применения по п.4, состоящая из Lactobacillus salivarius (LS01) DSM 22775, Bifidobacterium breve (BR03) DSM 16604 и L.pentosus (LPS01) DSM 21980.
6. Композиция для применения по п.4, состоящая из Lactobacillus salivarius (LS01) DSM 22775 и Bifidobacterium breve (BR03) DSM 16604.
7. Композиция для применения по п.1, где указанные бактериальные культуры представлены в указанных композициях в форме живых бактерий, мертвых бактерий или клеточных компонентов, клеточных экстрактов или их лизатов.
8. Композиция для применения по п.1 в твердой форме для перорального введения.
9. Композиция для применения по п.1, где указанные культуры пробиотических бактерий присутствуют в концентрации, составляющей от 1×107 до 1×1011 КОЕ (колониеобразующая единица)/г композиции, предпочтительно от 1×108 до 1×1010 КОЕ/г композиции.
10. Композиция для применения по п.1, дополнительно содержащая диетические волокна с пребиотической активностью, выбранные из фруктоолигосахаридов (FOS), инулина и частично гидролизованной гуаровой камеди (PHGG).
11. Композиция для применения по п.1, представляющая собой фармацевтическую, диетическую, пищевую или нутрицевтическую композицию.
12. Применение по меньшей мере одной культуры пробиотических бактерий, выбранной из группы, включающей следующие культуры бактерий, депонированные в Deutsche Sammlung und Mikroorganismen und Zellkulturen GmbH (DSMZ):
Lactobacillus salivarius (LS01) DSM 22775, депонированный 23.07.2009;
Bifidobacterium breve (BR03) DSM 16604, депонированный 20.07.2004;
Lactobacillus pentosus (LPS01) DSM 21980, депонированный 14.11.2008;
Streptococcus thermophilus (FP4) DSM 18616, депонированный 13.09.2006;
Lactobacillus casei ssp. rhamnosus (LR04) DSM 16605, депонированный 20.07.2004; и
Lactobacillus acidophilus (LA02) DSM 21717, депонированный 06.08.2008,
для применения в лечении патологий, ассоциированных с изменениями иммунной системы.
13. Применение по п.12, где указанная композиция предназначена для профилактического и/или терапевтического лечения патологий, ассоциированных с изменениями иммунной системы, выбранных из группы, включающей аллергии, атопию, аллергический ринит, пищевую гиперчувствительность, атопический дерматит, экзему, астму или иммунодефициты.
14. Применение по п.13, где указанная композиция предназначена для профилактического и/или терапевтического лечения атопического дерматита.
15. Применение по любому из пп.12-14, где указанная композиция представляет собой композицию по любому из пп.4-11.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2010A000375A IT1398553B1 (it) | 2010-03-08 | 2010-03-08 | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
| ITMI2010A000375 | 2010-03-08 | ||
| PCT/IB2011/000490 WO2011110918A1 (en) | 2010-03-08 | 2011-03-07 | Composition comprising probiotic bacteria for use in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016129186A Division RU2712751C9 (ru) | 2010-03-08 | 2011-03-07 | Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012140052A true RU2012140052A (ru) | 2014-04-20 |
| RU2605293C2 RU2605293C2 (ru) | 2016-12-20 |
Family
ID=42942117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012140052/15A RU2605293C2 (ru) | 2010-03-08 | 2011-03-07 | Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств |
| RU2016129186A RU2712751C9 (ru) | 2010-03-08 | 2011-03-07 | Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016129186A RU2712751C9 (ru) | 2010-03-08 | 2011-03-07 | Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8734783B2 (ru) |
| EP (2) | EP2626076B1 (ru) |
| JP (2) | JP5931754B2 (ru) |
| KR (1) | KR101872946B1 (ru) |
| CN (2) | CN103037876B (ru) |
| AU (1) | AU2011225798B2 (ru) |
| BR (1) | BR112012022755B1 (ru) |
| CA (1) | CA2792343C (ru) |
| DK (2) | DK2626076T3 (ru) |
| ES (2) | ES2581803T3 (ru) |
| HU (2) | HUE030888T2 (ru) |
| IT (1) | IT1398553B1 (ru) |
| PL (2) | PL2544698T3 (ru) |
| PT (2) | PT2626076T (ru) |
| RU (2) | RU2605293C2 (ru) |
| UA (1) | UA111715C2 (ru) |
| WO (1) | WO2011110918A1 (ru) |
| ZA (2) | ZA201207377B (ru) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1398553B1 (it) | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
| WO2011149335A1 (en) * | 2010-05-25 | 2011-12-01 | N.V. Nutricia | Immune imprinting nutritional composition |
| IT1403661B1 (it) | 2011-01-28 | 2013-10-31 | Probiotical Spa | Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali. |
| ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
| ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
| ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| ITRM20110477A1 (it) | 2011-09-09 | 2013-03-10 | Giovanni Mogna | Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell |
| ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP2836224A4 (en) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| SG11201503966PA (en) | 2012-11-23 | 2015-06-29 | Seres Health Inc | Synergistic bacterial compositions and methods of production and use thereof |
| ITMI20122270A1 (it) | 2012-12-31 | 2014-07-01 | Giovanni Mogna | Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie. |
| JP2016509003A (ja) | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| US10973861B2 (en) | 2013-02-04 | 2021-04-13 | Seres Therapeutics, Inc. | Compositions and methods |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| FR3004349B1 (fr) * | 2013-04-15 | 2015-11-27 | Greentech | Applications cosmetiques et pharmaceutiques de lactobacillus pentosus |
| ITMI20130795A1 (it) * | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat |
| ITMI20130793A1 (it) * | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
| US10165788B2 (en) * | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
| CN105979952B (zh) | 2013-11-25 | 2022-04-08 | 赛里斯治疗公司 | 协同细菌组合物以及其制造方法和用途 |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| EP3223836A1 (en) * | 2014-11-26 | 2017-10-04 | Probiotical S.p.A. | Strains of lactobacillus or bifidobacterium for maintaining homeostasis |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| AR103260A1 (es) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| KR20170104471A (ko) | 2014-12-29 | 2017-09-15 | 모핀 에스.알.엘. | 유산균 함유 도우를 이용한 고 소화성의 이스트 무첨가 피자의 제조 방법 |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| ITUB20155700A1 (it) * | 2015-11-18 | 2017-05-18 | Probiotical Spa | Composizioni con azione sinergica tra un complesso gelificante muco-aderente contro il passaggio degli antigeni, e batteri immunomodulanti anti-IL17 per uso nel trattamento delle malattie autoimmuni e neurodegenerative IL17 dipendenti. |
| ITUB20155752A1 (it) * | 2015-11-19 | 2017-05-19 | Probiotical Spa | Composizione di batteri per uso per attenuare le diminuzioni di prestazione dopo un esercizio fisico che danneggia i muscoli. |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| JP6347268B2 (ja) * | 2016-02-26 | 2018-06-27 | トヨタ自動車株式会社 | 複合活物質の製造方法 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| ME03487B (me) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti |
| ITUA20162013A1 (it) | 2016-03-24 | 2017-09-24 | Probiotical Spa | Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica. |
| ITUA20164065A1 (it) * | 2016-06-01 | 2017-12-01 | Probiotical Spa | Composizioni in gel per applicazioni topiche a base di batteri, preparazione delle stesse e loro usi. |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| KR102205829B1 (ko) | 2017-06-14 | 2021-01-21 | 기초과학연구원 | 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 |
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| RU2699540C2 (ru) * | 2017-08-17 | 2019-09-06 | Павел Павлович Несмиянов | Композиция, содержащая пробиотические бактерии или их компоненты, и способ ее применения в лечении иммунных заболеваний кожи |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| BR112020008552A2 (pt) | 2017-10-30 | 2020-12-29 | Seres Therapeutics, Inc. | métodos e composições para tratamento de resistência a antibiótico |
| SG11202005863TA (en) | 2018-01-12 | 2020-07-29 | Gi Innovation Inc | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof |
| CN110710627A (zh) * | 2018-07-12 | 2020-01-21 | 序瑞生物科技(上海)有限公司 | 一种功能性益生菌固体饮料及其制备方法 |
| EP3823651A4 (en) | 2018-07-19 | 2022-04-27 | Pendulum Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION |
| KR102130646B1 (ko) * | 2018-10-15 | 2020-07-06 | 주식회사 제일바이오 | 신규한 락토바실러스 살리바리우스 및 이를 유효성분으로 포함하는 양식 어류 및 갑각류용 사료첨가제 |
| ES3053838T3 (en) * | 2019-03-07 | 2026-01-27 | Probiotical Spa | Mixture of probiotic bacteria strains for use in the treatment of allergic asthma and with recurrent wheezing, preferably in paediatric subjects |
| CN110616167B (zh) * | 2019-08-22 | 2022-02-01 | 江南大学 | 能够缓解特应性皮炎的双歧杆菌及其应用 |
| CN110643541B (zh) * | 2019-10-25 | 2021-08-24 | 江南大学 | 一株可调节过敏性哮喘Th2/Th1平衡的干酪乳杆菌及其应用 |
| WO2021138599A1 (en) * | 2020-01-03 | 2021-07-08 | Forte Subsidiary, Inc. | Cosmetic compositions |
| KR102152878B1 (ko) * | 2020-03-02 | 2020-09-07 | 주식회사 잇츠한불 | 락토바실러스 펜토서스 균주 및 이를 포함하는 미생물 균총 개선 및 피부 장벽 개선용 조성물 |
| CN111528479A (zh) * | 2020-05-15 | 2020-08-14 | 深圳爱米基因科技有限责任公司 | 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用 |
| CN111700917B (zh) * | 2020-06-18 | 2022-08-09 | 江南大学 | 一种用于预防和/或治疗特应性皮炎的产品 |
| CN111840335A (zh) * | 2020-07-07 | 2020-10-30 | 刘平祥 | 一种含有益生菌的组合物及其在气管炎哮喘上的应用 |
| IT202000018901A1 (it) * | 2020-07-31 | 2022-01-31 | Synbalance Srl | Composizioni probiotiche e loro uso nella prevenzione e/o nel trattamento di patologie e/o disturbi della pelle |
| WO2022024023A1 (en) * | 2020-07-31 | 2022-02-03 | Roelmi HPC s.r.l. | Probiotic compositions and their use to modulate immune systems |
| CN111944727B (zh) * | 2020-08-24 | 2021-12-03 | 汤臣倍健股份有限公司 | 一种短双歧杆菌207-1及其应用 |
| JP6928195B1 (ja) * | 2021-05-21 | 2021-09-01 | 国立大学法人東京工業大学 | 免疫鎮静作用を有する乳酸菌 |
| CN114304642A (zh) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | 一种用于过敏的益生菌产品 |
| CN115428954A (zh) * | 2022-09-15 | 2022-12-06 | 北京三元食品股份有限公司 | 复合益生菌及发酵乳在制备用于辅助治疗hiv患者产品中的应用 |
| WO2025047884A1 (ja) | 2023-08-31 | 2025-03-06 | 森永乳業株式会社 | 細菌、組成物及び組成物の製造方法 |
| WO2025047886A1 (ja) | 2023-08-31 | 2025-03-06 | 森永乳業株式会社 | セロトニン産生促進用組成物 |
| CN119112955B (zh) * | 2024-11-12 | 2025-01-14 | 内蒙古自治区农牧业科学院 | 一种复合乳酸菌奶牛蹄浴液的制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001999A (es) * | 2001-09-05 | 2004-07-16 | Vsl Pharmaceuticals Inc | Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia. |
| GB0124580D0 (en) * | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| FR2853908B1 (fr) * | 2003-04-16 | 2005-06-03 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| PL1675481T3 (pl) * | 2003-10-24 | 2009-03-31 | Nutricia Nv | Kompozycja synbiotyczna dla niemowląt |
| WO2006013588A1 (en) * | 2004-08-05 | 2006-02-09 | Anidral S.R.L. | Folic acid producing bifidobacterium bacterial strains, formulations and use thereof |
| ITMI20042189A1 (it) * | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
| KR100479719B1 (ko) * | 2005-01-29 | 2005-03-31 | 주식회사 프로바이오닉 | 유해 병원성 미생물 생육 억제능 및 항알레르기성을 갖는 신규 내산성 락토바실러스 사케이 Ｐｒｏｂｉｏ-65 |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| CN101969966B (zh) * | 2007-12-07 | 2013-05-08 | 努特里希亚公司 | 用于尘螨变态反应的双歧杆菌 |
| DK2213178T3 (da) | 2009-01-28 | 2013-03-04 | Metalquimia Sa | Behandlingsenhed med tvungen konvektion til et kødprodukt skåret i skiver og en fremgangsmåde til behandling af et kødprodukt under anvendelse af førnævnte enhed |
| IT1400821B1 (it) * | 2009-03-09 | 2013-07-02 | Probiotical Spa | Sospensione oleosa contenente batteri probiotici per uso pediatrico |
| US20110064777A1 (en) * | 2009-09-11 | 2011-03-17 | Sharad Mohan | Live lactobacillus soap and method for delivering lactobacillus to skin tissue |
| IT1398553B1 (it) * | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
-
2010
- 2010-03-08 IT ITMI2010A000375A patent/IT1398553B1/it active
-
2011
- 2011-03-07 PL PL11717732T patent/PL2544698T3/pl unknown
- 2011-03-07 ES ES11717732.9T patent/ES2581803T3/es active Active
- 2011-03-07 CN CN201180019385.0A patent/CN103037876B/zh active Active
- 2011-03-07 CA CA2792343A patent/CA2792343C/en active Active
- 2011-03-07 EP EP13166218.1A patent/EP2626076B1/en active Active
- 2011-03-07 US US13/583,477 patent/US8734783B2/en active Active
- 2011-03-07 RU RU2012140052/15A patent/RU2605293C2/ru active
- 2011-03-07 PL PL13166218T patent/PL2626076T3/pl unknown
- 2011-03-07 CN CN201510082517.4A patent/CN104800247A/zh active Pending
- 2011-03-07 KR KR1020127026327A patent/KR101872946B1/ko active Active
- 2011-03-07 ES ES13166218.1T patent/ES2603629T3/es active Active
- 2011-03-07 AU AU2011225798A patent/AU2011225798B2/en not_active Ceased
- 2011-03-07 HU HUE13166218A patent/HUE030888T2/en unknown
- 2011-03-07 HU HUE11717732A patent/HUE029245T2/en unknown
- 2011-03-07 DK DK13166218.1T patent/DK2626076T3/en active
- 2011-03-07 PT PT131662181T patent/PT2626076T/pt unknown
- 2011-03-07 WO PCT/IB2011/000490 patent/WO2011110918A1/en not_active Ceased
- 2011-03-07 EP EP11717732.9A patent/EP2544698B1/en active Active
- 2011-03-07 PT PT117177329T patent/PT2544698T/pt unknown
- 2011-03-07 RU RU2016129186A patent/RU2712751C9/ru active
- 2011-03-07 DK DK11717732.9T patent/DK2544698T3/en active
- 2011-03-07 JP JP2012556603A patent/JP5931754B2/ja active Active
- 2011-03-07 BR BR112012022755-6A patent/BR112012022755B1/pt not_active IP Right Cessation
- 2011-07-03 UA UAA201211024A patent/UA111715C2/uk unknown
-
2012
- 2012-10-02 ZA ZA2012/07377A patent/ZA201207377B/en unknown
-
2014
- 2014-05-23 US US14/286,308 patent/US9498503B2/en active Active
- 2014-12-18 ZA ZA2014/09369A patent/ZA201409369B/en unknown
-
2016
- 2016-02-18 JP JP2016029244A patent/JP6182628B2/ja active Active
- 2016-10-14 US US15/294,464 patent/US9931363B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012140052A (ru) | Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств | |
| EP2831287B1 (en) | Composition based on strains of bifidobacterium longum bacteria capable of helping to prolong life | |
| SI3048165T1 (en) | NEW SEV BACTERIA BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND ITS APPLICATION FOR INJURY AND / OR PREVENTION OF OVERVIEW OF BODY WEALTH AND BALANCE AND ASSOCIATED DISEASES | |
| JP4683881B2 (ja) | 抗腫瘍活性剤 | |
| RU2011139211A (ru) | Бактериальные штаммы, обладающие высокой противовоспалительной активностью | |
| Isolauri | The role of probiotics in paediatrics | |
| CN112375727B (zh) | 乳铁蛋白在促进双歧杆菌、乳酸杆菌增殖中的应用 | |
| CA2893822C (en) | Strain of bifidobacterium animalis ssp. animalis | |
| RU2008139598A (ru) | Синбиотическая смесь | |
| RU2011150216A (ru) | Детские питательные смеси, содержащие пробиотические микроорганизмы | |
| RU2013126616A (ru) | Замороженные кондитерские изделия, содержащие пробиотические микроорганизмы | |
| US11931388B2 (en) | Postbiotic extract and preparation process and use thereof | |
| Kailasapathy | Commercial sources of probiotic strains and their validated and potential health benefits-a review | |
| Korbekandi et al. | Evaluation of probiotic yoghurt produced by Lactobacillus paracasei ssp. tolerans | |
| Cukrowska et al. | Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis | |
| Mancuskova et al. | The medical functions of probiotics and their role in clinical nutrition | |
| Ladda et al. | Anti-inflammatory effect of probiotic Lactobacillus paracasei MSMC39-1 on alcohol-induced hepatitis in rats | |
| Meena et al. | Specific immune response of oral administration of Dahi and milk fermented with Lactobacillus helveticus against Salmonella enteritidis in mice | |
| Kabiri et al. | Inhibitiory properties of cytoplasmic extract of Lactobacilli isolated from common carp intestine on human chronic myelocytic leukemia K562 cell line: an in vitro study. | |
| Ahn | The Preventive and Therapeutic Effect of Probiotics in Allergic Diseases | |
| LI et al. | Research and application progress of novel functional strains in fermented dairy products. | |
| RU2007104090A (ru) | БАКТЕРИАЛЬНЫЕ ШТАММЫ Bifidobacterium, ПРОДУЦИРУЮЩИЕ ФОЛИЕВУЮ КИСЛОТУ, ПРЕПАРАТЫ И ИХ ПРИМЕНЕНИЕ | |
| Reismaa | Piimhappebakterite mõju inimese tervisele | |
| EA201370135A1 (ru) | Синбиотические кисломолочные продукты, напитки и инкапсулированные бактериальные соединения, обогащенные штаммом lactobacillus acidophilus proviti, и их применение | |
| Chaiyasut et al. | Different strains of heat-killed Lactobacilli affected adhesion on Caco-2 and induced interleukin-6, interleukin-10 and interleukin-12 production |